CS
TPST icon

Credit Suisse’s Tempest Therapeutics TPST Stock Holding History

Credit Suisse’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-97
Closed -$40K – 4560
2020
Q4 		$40K Buy
97
+2
+2% +$691 ﹤0.01% 4269
2020
Q3 		$30K Sell
95
-3
-3% -$1.02K ﹤0.01% 3976
2020
Q2 		$33K Buy
+98
New +$39.1K ﹤0.01% 3898
2017
Q1 		– Sell
-31
Closed -$138K – 4058
2016
Q4 		$138K Buy
31
+22
+244% +$274K ﹤0.01% 3896
2016
Q3 		$185K Hold
9
– – ﹤0.01% 3832
2016
Q2 		$137K Buy
9
+3
+50% +$68.5K ﹤0.01% 3995
2016
Q1 		$167K Sell
6
-8
-57% -$169K ﹤0.01% 3731
2015
Q4 		$405K Buy
14
+5
+56% +$165K ﹤0.01% 3525
2015
Q3 		$228K Sell
9
-17
-65% -$1.14M ﹤0.01% 3865
2015
Q2 		$2.23M Buy
26
+3
+13% +$275K ﹤0.01% 2472
2015
Q1 		$2.29M Buy
23
+12
+109% +$1.6M ﹤0.01% 2273
2014
Q4 		$1.47M Buy
+11
New +$806K ﹤0.01% 2817
2014
Q2 		– Sell
-4
Closed -$106K – 4803
2014
Q1 		$106K Buy
+4
New +$113K ﹤0.01% 4506

Other funds holding TPST

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Credit Suisse's TPST Position: Q1 2021 in Review

Credit Suisse sold out of Tempest Therapeutics (TPST) in Q1 2021, closing a stake of 97 shares — an estimated $40K sold.

Credit Suisse first reported a position in TPST in Q1 2014 and held it in 13 quarters. The position peaked at $2.29M in Q1 2015. 30 funds tracked by Wall St. Rank hold TPST as of Q1 2021.

  • Credit Suisse reported no remaining Tempest Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Credit Suisse sold 97 Tempest Therapeutics shares in Q1 2021, an estimated $40K.
  • Credit Suisse first reported a position in Tempest Therapeutics in Q1 2014 and held it in 13 quarters.
  • Credit Suisse's Tempest Therapeutics position peaked at $2.29M in Q1 2015.
  • 30 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2021.

Based on Credit Suisse's 13F filing for Q1 2021, filed 14 May 2021.